Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus SOX versus SOX as first-line therapy for advanced gastric cancer
ChiCTR1800020047Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib, oxaliplatin and tegafur + gimeracil + oteracil in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
anlotiniboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800020047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020047.